Global Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity

You are here: 麻豆原创 Catalog Pharma & Healthcare Research & Development (Pharma & Healthcare) Pharmaceutical Manufacturing

Global Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity

麻豆原创 Research Report Summary

Global Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity report is published on November 30, 2023 and has 211 pages in it. This market research report provides information about Research & Development (Pharma & Healthcare), Pharmaceutical Manufacturing, Pharma & Healthcare industry. It covers Global market data and forecasts. It is priced starting at USD 3,200.00 for Single User License (PDF) which allows one person to use this report.

Please read the description and table of contents of this research report given below to check whether it meets your research requirements. If not, then please do not hesitate to contact us using "Report Enquiry" form given below. We can customize this research report or suggest a new fully customized market research report to meet your research goals and data requirements.

Global Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity

Printer version

Send by email

Publication ID:听

GRM0223074

Publication Date:听

November 30, 2023

笔补驳别蝉:听

211

笔耻产濒颈蝉丑别谤:听

Grace 麻豆原创 Data

颁辞耻苍迟谤颈别蝉:听

Global

USD 3,200.00

Pay By Invoice

If you wish to purchase this report using bank/wire transfer against an invoice, please fill your details using request invoice form given below.

Globally Trusted Brand

We help executives from firms听to Start-ups听with their market research needs thus听we can help you too.听

Secure Checkout

You can shop confidently as your online payments are processed using PCI DSS compliant secure payment gateways on our website.

Frequently Asked Questions

If you have any pre-sales听questions related to this report please let us know using the "Report Enquiry" form below. This will help us provide you听with answers听so that you can purchase with confidence. If you wish to read about frequently asked questions by our customers please visit our .

Tabs

Description

Global preventive vaccines market will reach $120.07 billion by 2032, growing by 6.4% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 111 tables and 87 figures, this 211-page report 鈥淕lobal Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire global preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Region.

Based on Vaccine Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Live/Attenuated Vaccines
鈥� Inactivated Vaccines
鈥� Subunit Vaccines
鈥� Toxoid Vaccines
鈥� Conjugate Vaccines
鈥� mRNA Vaccines
鈥� Recombinant Vector Vaccines
鈥� Other Vaccines

Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Pneumococcal Disease
鈥� Poliovirus
鈥� Hepatitis
鈥� Influenza
鈥� Measles, Mumps, and Rubella (MMR)
鈥� Varicella
鈥� Human Papilloma Virus
鈥� COVID-19
鈥� Other Diseases

By Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Intramuscular Route
鈥� Subcutaneous Route
鈥� Oral Route
鈥� Intravenous Injection
鈥� Other Administration Routes

By Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
鈥� Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
鈥� Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases

Geographically, the following regions together with the listed national/local markets are fully investigated:
鈥� North America (U.S., Canada, and Mexico)
鈥� Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
鈥� APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
鈥� South America (Brazil, Chile, Argentina, Rest of South America)
鈥� MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
For each region and country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of all regional markets by country and the breakdown of each national market by Vaccine Type, Disease, and Administration over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

Table of Contents

1 Introduction 10
1.1 Industry Definition and Research Scope 10
1.1.1 Industry Definition 10
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of 麻豆原创 Research Methodology 14
1.2.2 麻豆原创 Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 16
1.2.6 麻豆原创 Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 麻豆原创 Overview and Dynamics 22
2.1 麻豆原创 Size and Forecast 22
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the 麻豆原创 27
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 29
2.2 Major Growth Drivers 33
2.3 麻豆原创 Restraints and Challenges 39
2.4 Emerging Opportunities and 麻豆原创 Trends 42
2.5 Porter鈥檚 Fiver Forces Analysis 46
3 Segmentation of Global 麻豆原创 by Vaccine Type 50
3.1 麻豆原创 Overview by Vaccine Type 50
3.2 Live/Attenuated Vaccines 52
3.3 Inactivated Vaccines 53
3.4 Subunit Vaccines 54
3.5 Toxoid Vaccines 55
3.6 Conjugate Vaccines 56
3.7 mRNA Vaccines 57
3.8 Recombinant Vector Vaccines 58
3.9 Other Vaccines 59
4 Segmentation of Global 麻豆原创 by Disease 60
4.1 麻豆原创 Overview by Disease 60
4.2 Pneumococcal Disease 62
4.3 Poliovirus 63
4.4 Hepatitis 64
4.5 Influenza 65
4.6 Measles, Mumps, and Rubella (MMR) 66
4.7 Varicella 67
4.8 Human Papilloma Virus 68
4.9 COVID-19 69
4.10 Other Diseases 70
5 Segmentation of Global 麻豆原创 by Administration 71
5.1 麻豆原创 Overview by Administration 71
5.2 Intramuscular Route 73
5.3 Subcutaneous Route 74
5.4 Oral Route 75
5.5 Intravenous Injection 76
5.6 Other Administration Routes 77
6 Segmentation of Global 麻豆原创 by Patient 78
6.1 麻豆原创 Overview by Patient 78
6.2 Pediatric Vaccines 80
6.3 Adult Vaccines 82
7 Segmentation of Global 麻豆原创 by Region 84
7.1 Geographic 麻豆原创 Overview 2022-2032 84
7.2 North America 麻豆原创 2022-2032 by Country 88
7.2.1 Overview of North America 麻豆原创 88
7.2.2 U.S. 92
7.2.3 Canada 96
7.2.4 Mexico 99
7.3 European 麻豆原创 2022-2032 by Country 102
7.3.1 Overview of European 麻豆原创 102
7.3.2 Germany 106
7.3.3 U.K. 109
7.3.4 France 112
7.3.5 Spain 115
7.3.6 Italy 118
7.3.7 Russia 121
7.3.8 Rest of European 麻豆原创 124
7.4 Asia-Pacific 麻豆原创 2022-2032 by Country 126
7.4.1 Overview of Asia-Pacific 麻豆原创 126
7.4.2 Japan 130
7.4.3 China 134
7.4.4 Australia 137
7.4.5 India 140
7.4.6 South Korea 143
7.4.7 Rest of APAC Region 146
7.5 South America 麻豆原创 2022-2032 by Country 148
7.5.1 Argentina 151
7.5.2 Brazil 154
7.5.3 Chile 157
7.5.4 Rest of South America 麻豆原创 160
7.6 MEA 麻豆原创 2022-2032 by Country 161
7.6.1 UAE 164
7.6.2 Saudi Arabia 167
7.6.3 South Africa 170
7.6.4 Other National 麻豆原创s 173
8 Competitive Landscape 174
8.1 Overview of Key Vendors 174
8.2 New Product Launch, Partnership, Investment, and M&A 177
8.3 Company Profiles 178
AstraZeneca plc 178
Bavarian Nordic A/S 180
China National Biotec Group Company Ltd. 183
CSL Ltd. 185
Daiichi Sankyo Co. Ltd 187
Emergent BioSolutions Inc. 189
GlaxoSmithKline plc 191
Johnson & Johnson 195
Merck & Co. 197
Moderna Inc. 199
Novavax, Inc. 200
Pfizer Inc. 202
Sanofi SA 206
Takeda Pharmaceutical Co. Ltd. 209
RELATED REPORTS 211

List of Tables:

Table 1. Snapshot of Global Preventive Vaccines 麻豆原创 in Balanced Perspective, 2022-2032 20
Table 2. World Economic Outlook, 2021-2031 25
Table 3. World Economic Outlook, 2021-2023 26
Table 4. Scenarios for Economic Impact of Ukraine Crisis 30
Table 5. World Health Spending by Region, $ bn, 2013-2020 38
Table 6. Main Product Trends and 麻豆原创 Opportunities in Global Preventive Vaccines 麻豆原创 42
Table 7. Global Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 50
Table 8. Global Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 60
Table 9. Global Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 71
Table 10. Global Preventive Vaccines 麻豆原创 by Patient, 2022-2032, $ mn 78
Table 11. Global Preventive Vaccines 麻豆原创: Pediatric Vaccines by Disease, 2022-2032, $ mn 81
Table 12. Global Preventive Vaccines 麻豆原创: Adult Vaccines by Disease, 2022-2032, $ mn 83
Table 13. Global Preventive Vaccines 麻豆原创 by Region, 2022-2032, $ mn 85
Table 14. Leading National Preventive Vaccines 麻豆原创, 2022 and 2032, $ mn 87
Table 15. North America Preventive Vaccines 麻豆原创 by Country, 2022-2032, $ mn 90
Table 16. U.S. Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 94
Table 17. U.S. Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 94
Table 18. U.S. Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 95
Table 19. Canada Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 97
Table 20. Canada Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 97
Table 21. Canada Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 98
Table 22. Mexico Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 100
Table 23. Mexico Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 100
Table 24. Mexico Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 101
Table 25. Europe Preventive Vaccines 麻豆原创 by Country, 2022-2032, $ mn 105
Table 26. Germany Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 107
Table 27. Germany Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 107
Table 28. Germany Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 108
Table 29. U.K. Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 110
Table 30. U.K. Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 110
Table 31. U.K. Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 111
Table 32. France Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 113
Table 33. France Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 113
Table 34. France Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 114
Table 35. Spain Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 116
Table 36. Spain Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 116
Table 37. Spain Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 117
Table 38. Italy Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 119
Table 39. Italy Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 119
Table 40. Italy Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 120
Table 41. Russia Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 122
Table 42. Russia Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 122
Table 43. Russia Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 123
Table 44. Preventive Vaccines 麻豆原创 in Rest of Europe by Country, 2022-2032, $ mn 125
Table 45. APAC Preventive Vaccines 麻豆原创 by Country, 2022-2032, $ mn 128
Table 46. Japan Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 132
Table 47. Japan Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 132
Table 48. Japan Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 133
Table 49. China Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 135
Table 50. China Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 135
Table 51. China Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 136
Table 52. Australia Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 138
Table 53. Australia Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 138
Table 54. Australia Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 139
Table 55. India Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 141
Table 56. India Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 141
Table 57. India Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 142
Table 58. South Korea Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 144
Table 59. South Korea Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 144
Table 60. South Korea Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 145
Table 61. Preventive Vaccines 麻豆原创 in Rest of APAC by Country/Region, 2022-2032, $ mn 147
Table 62. South America Preventive Vaccines 麻豆原创 by Country, 2022-2032, $ mn 150
Table 63. Argentina Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 152
Table 64. Argentina Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 152
Table 65. Argentina Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 153
Table 66. Brazil Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 155
Table 67. Brazil Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 155
Table 68. Brazil Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 156
Table 69. Chile Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 158
Table 70. Chile Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 158
Table 71. Chile Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 159
Table 72. MEA Preventive Vaccines 麻豆原创 by Country, 2022-2032, $ mn 163
Table 73. UAE Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 165
Table 74. UAE Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 165
Table 75. UAE Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 166
Table 76. Saudi Arabia Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 168
Table 77. Saudi Arabia Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 168
Table 78. Saudi Arabia Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 169
Table 79. South Africa Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, $ mn 171
Table 80. South Africa Preventive Vaccines 麻豆原创 by Disease, 2022-2032, $ mn 171
Table 81. South Africa Preventive Vaccines 麻豆原创 by Administration, 2022-2032, $ mn 172
Table 82. AstraZeneca plc: Company Snapshot 178
Table 83. AstraZeneca plc: Business Segmentation 179
Table 84. AstraZeneca plc: Product Portfolio 179
Table 85. Bavarian Nordic A/S: Company Snapshot 180
Table 86. Bavarian Nordic A/S: 麻豆原创ed Products and Pipeline, as of July 2020 181
Table 87. China National Biotec Group Company Ltd.: Company Snapshot 183
Table 88. CSL Ltd.: Company Snapshot 185
Table 89. Daiichi Sankyo Co. Ltd.: Company Snapshot 187
Table 90. Emergent BioSolutions Inc.: Company Snapshot 189
Table 91. GlaxoSmithKline: Company Snapshot 191
Table 92. GlaxoSmithKline: Business Segmentation 192
Table 93. GlaxoSmithKline: Product Portfolio 193
Table 94. GlaxoSmithKline: Revenue, 2018-2020, $ bn 194
Table 95. GlaxoSmithKline: Recent Developments 194
Table 96. Johnson & Johnson: Company Snapshot 195
Table 97. Johnson & Johnson: Business Segments 196
Table 98. Merck & Co., Inc.: Company Snapshot 197
Table 99. Merck & Co., Inc.: Business Segmentation 197
Table 100. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 198
Table 101. Moderna Inc.: Company Snapshot 199
Table 102. Novavax, Inc.: Company Snapshot 200
Table 103. Pfizer Inc.: Company Snapshot 202
Table 104. Pfizer Inc.: Business Segmentation 203
Table 105. Pfizer Inc.: Product Portfolio 204
Table 106. Pfizer Inc.: Revenue, 2018-2020, $ bn 205
Table 107. Pfizer Inc.: Recent Developments 205
Table 108. Sanofi: Company Snapshot 206
Table 109. Sanofi: Business Segmentation 206
Table 110. Sanofi: Revenue, 2018-2020, $ bn 208
Table 111. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 209

List of Figures:

Figure 1. Research Method Flow Chart 14
Figure 2. Bottom-up Approach and Top-down Approach for 麻豆原创 Estimation 17
Figure 3. Global 麻豆原创 Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 19
Figure 4. Global Preventive Vaccines 麻豆原创, 2022-2032, $ mn 22
Figure 5. Development Stages of Preventive Vaccines 23
Figure 6. Impact of COVID-19 on Business 27
Figure 7. Primary Drivers and Impact Factors of Global Preventive Vaccines 麻豆原创 33
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 36
Figure 9. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million 37
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 37
Figure 11. Primary Restraints and Impact Factors of Global Preventive Vaccines 麻豆原创 39
Figure 12. Investment Opportunity Analysis 43
Figure 13. Porter鈥檚 Fiver Forces Analysis of Global Preventive Vaccines 麻豆原创 46
Figure 14. Breakdown of Global Preventive Vaccines 麻豆原创 by Vaccine Type, 2022-2032, % of Revenue 51
Figure 15. Global Addressable 麻豆原创 Cap in 2023-2032 by Vaccine Type, Value ($ mn) and Share (%) 51
Figure 16. Global Preventive Vaccines 麻豆原创 by Vaccine Type: Live/Attenuated Vaccines, 2022-2032, $ mn 52
Figure 17. Global Preventive Vaccines 麻豆原创 by Vaccine Type: Inactivated Vaccines, 2022-2032, $ mn 53
Figure 18. Global Preventive Vaccines 麻豆原创 by Vaccine Type: Subunit Vaccines, 2022-2032, $ mn 54
Figure 19. Global Preventive Vaccines 麻豆原创 by Vaccine Type: Toxoid Vaccines, 2022-2032, $ mn 55
Figure 20. Global Preventive Vaccines 麻豆原创 by Vaccine Type: Conjugate Vaccines, 2022-2032, $ mn 56
Figure 21. Global Preventive Vaccines 麻豆原创 by Vaccine Type: mRNA Vaccines, 2022-2032, $ mn 57
Figure 22. Global Preventive Vaccines 麻豆原创 by Vaccine Type: Recombinant Vector Vaccines, 2022-2032, $ mn 58
Figure 23. Global Preventive Vaccines 麻豆原创 by Vaccine Type: Other Vaccines, 2022-2032, $ mn 59
Figure 24. Breakdown of Global Preventive Vaccines 麻豆原创 by Disease, 2022-2032, % of Sales Revenue 61
Figure 25. Global Addressable 麻豆原创 Cap in 2023-2032 by Disease, Value ($ mn) and Share (%) 61
Figure 26. Global Preventive Vaccines 麻豆原创 by Disease: Pneumococcal Disease, 2022-2032, $ mn 62
Figure 27. Global Preventive Vaccines 麻豆原创 by Disease: Poliovirus, 2022-2032, $ mn 63
Figure 28. Global Preventive Vaccines 麻豆原创 by Disease: Hepatitis, 2022-2032, $ mn 64
Figure 29. Global Preventive Vaccines 麻豆原创 by Disease: Influenza, 2022-2032, $ mn 65
Figure 30. Global Preventive Vaccines 麻豆原创 by Disease: Measles, Mumps, and Rubella (MMR), 2022-2032, $ mn 66
Figure 31. Global Preventive Vaccines 麻豆原创 by Disease: Varicella, 2022-2032, $ mn 67
Figure 32. Global Preventive Vaccines 麻豆原创 by Disease: Human Papilloma Virus, 2022-2032, $ mn 68
Figure 33. Global Preventive Vaccines 麻豆原创 by Disease: COVID-19, 2022-2032, $ mn 69
Figure 34. Global Preventive Vaccines 麻豆原创 by Disease: Other Diseases, 2022-2032, $ mn 70
Figure 35. Breakdown of Global Preventive Vaccines 麻豆原创 by Administration, 2022-2032, % of Sales Revenue 72
Figure 36. Global Addressable 麻豆原创 Cap in 2023-2032 by Administration, Value ($ mn) and Share (%) 72
Figure 37. Global Preventive Vaccines 麻豆原创 by Administration: Intramuscular Route, 2022-2032, $ mn 73
Figure 38. Global Preventive Vaccines 麻豆原创 by Administration: Subcutaneous Route, 2022-2032, $ mn 74
Figure 39. Global Preventive Vaccines 麻豆原创 by Administration: Oral Route, 2022-2032, $ mn 75
Figure 40. Global Preventive Vaccines 麻豆原创 by Administration: Intravenous Injection, 2022-2032, $ mn 76
Figure 41. Global Preventive Vaccines 麻豆原创 by Administration: Other Administration Routes, 2022-2032, $ mn 77
Figure 42. Breakdown of Global Preventive Vaccines 麻豆原创 by Patient, 2022-2032, % of Revenue 79
Figure 43. Global Addressable 麻豆原创 Cap in 2023-2032 by Patient, Value ($ mn) and Share (%) 79
Figure 44. Global Preventive Vaccines 麻豆原创 by Patient: Pediatric Vaccines, 2022-2032, $ mn 80
Figure 45. Global Preventive Vaccines 麻豆原创 by Patient: Adult Vaccines, 2022-2032, $ mn 82
Figure 46. Global 麻豆原创 Snapshot by Region 84
Figure 47. Geographic Spread of Worldwide Preventive Vaccines 麻豆原创, 2022-2032, % of Sales Revenue 85
Figure 48. Global Addressable 麻豆原创 Cap in 2023-2032 by Region, Value ($ mn) and Share (%) 86
Figure 49. North American Preventive Vaccines 麻豆原创, 2022-2032, $ mn 89
Figure 50. Breakdown of North America Preventive Vaccines 麻豆原创 by Country, 2022 and 2032, % of Revenue 90
Figure 51. Contribution to North America 2023-2032 Cumulative 麻豆原创 by Country, Value ($ mn) and Share (%) 91
Figure 52. U.S. Preventive Vaccines 麻豆原创, 2022-2032, $ mn 93
Figure 53. Canada Preventive Vaccines 麻豆原创, 2022-2032, $ mn 96
Figure 54. Preventive Vaccines 麻豆原创 in Mexico, 2022-2032, $ mn 99
Figure 55. European Preventive Vaccines 麻豆原创, 2022-2032, $ mn 103
Figure 56. Breakdown of European Preventive Vaccines 麻豆原创 by Country, 2022 and 2032, % of Revenue 104
Figure 57. Contribution to Europe 2023-2032 Cumulative 麻豆原创 by Country, Value ($ mn) and Share (%) 105
Figure 58. Preventive Vaccines 麻豆原创 in Germany, 2022-2032, $ mn 106
Figure 59. Preventive Vaccines 麻豆原创 in U.K., 2022-2032, $ mn 109
Figure 60. Preventive Vaccines 麻豆原创 in France, 2022-2032, $ mn 112
Figure 61. Preventive Vaccines 麻豆原创 in Spain, 2022-2032, $ mn 115
Figure 62. Preventive Vaccines 麻豆原创 in Italy, 2022-2032, $ mn 118
Figure 63. Preventive Vaccines 麻豆原创 in Russia, 2022-2032, $ mn 121
Figure 64. Preventive Vaccines 麻豆原创 in Rest of Europe, 2022-2032, $ mn 124
Figure 65. Asia-Pacific Preventive Vaccines 麻豆原创, 2022-2032, $ mn 127
Figure 66. Breakdown of APAC Preventive Vaccines 麻豆原创 by Country, 2022 and 2032, % of Revenue 127
Figure 67. Contribution to APAC 2023-2032 Cumulative 麻豆原创 by Country, Value ($ mn) and Share (%) 129
Figure 68. Preventive Vaccines 麻豆原创 in Japan, 2022-2032, $ mn 131
Figure 69. Preventive Vaccines 麻豆原创 in China, 2022-2032, $ mn 134
Figure 70. Preventive Vaccines 麻豆原创 in Australia, 2022-2032, $ mn 137
Figure 71. Preventive Vaccines 麻豆原创 in India, 2022-2032, $ mn 140
Figure 72. Preventive Vaccines 麻豆原创 in South Korea, 2022-2032, $ mn 143
Figure 73. Preventive Vaccines 麻豆原创 in Rest of APAC, 2022-2032, $ mn 146
Figure 74. South America Preventive Vaccines 麻豆原创, 2022-2032, $ mn 149
Figure 75. Breakdown of South America Preventive Vaccines 麻豆原创 by Country, 2022 and 2032, % of Revenue 149
Figure 76. Contribution to South America 2023-2032 Cumulative 麻豆原创 by Country, Value ($ mn) and Share (%) 150
Figure 77. Preventive Vaccines 麻豆原创 in Argentina, 2022-2032, $ mn 151
Figure 78. Preventive Vaccines 麻豆原创 in Brazil, 2022-2032, $ mn 154
Figure 79. Preventive Vaccines 麻豆原创 in Chile, 2022-2032, $ mn 157
Figure 80. Preventive Vaccines 麻豆原创 in Rest of South America, 2022-2032, $ mn 160
Figure 81. Preventive Vaccines 麻豆原创 in Middle East and Africa (MEA), 2022-2032, $ mn 162
Figure 82. Breakdown of MEA Preventive Vaccines 麻豆原创 by Country, 2022 and 2032, % of Revenue 162
Figure 83. Contribution to MEA 2023-2032 Cumulative 麻豆原创 by Country, Value ($ mn) and Share (%) 163
Figure 84. Preventive Vaccines 麻豆原创 in UAE, 2022-2032, $ mn 164
Figure 85. Preventive Vaccines 麻豆原创 in Saudi Arabia, 2022-2032, $ mn 167
Figure 86. Preventive Vaccines 麻豆原创 in South Africa, 2022-2032, $ mn 170
Figure 87. Growth Stage of Global Preventive Vaccines Industry over the Forecast Period 174

Companies Covered

Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Enquiry / Request Invoice

Report Inquiry

Do you have more questions related to this market research report after going through the description and table of contents?

We are here to help. Please use the form given below to let us know your questions related to this report.

Kindly use your official email address and contact number to ensure speedy response.

First Name *

Last Name *

Company *

Email Address *

Phone (Including International Code) *

Report Title *

Do you need invoice for purchasing this report? *

Address 1

Address 2

City/Town

Postal/Zip Code

Country

License Type

Your Inquiry *

CAPTCHA

This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Research & Development (Pharma & Healthcare)

Pharmaceutical Manufacturing

Pharma & Healthcare

*Please note that the report cover image shown above is for representation purpose only. Actual report cover may vary.

听

Related 麻豆原创 Research Reports

Publication	Price
Global Retinol-binding Protein Immunoturbidimetric Assay Diagnostic Reagent 麻豆原创 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030 According to this latest study, the global Retinol-binding Protein Immunoturbidimetric Assay Diagnostic Reagent market size was valued at US$ xx million in 2023 and is forecast to a readjusted size of USD xx million by 2030 with a CAGR of xx% during review period. This report is a detailed and comprehensive analysis for global Retinol-binding Protein Immunoturbidimetric Assay Diagnostic Reagent market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided. Key Features: Global Retinol-binding Protein ...Read more	USD 3,480.00
North America Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure. Highlighted with 52 tables and 51 figures, this 132-page report 鈥淣orth America Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022...Read more	USD 2,600.00
Europe Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity Europe preventive vaccines market was valued at $18.02 billion in 2022 and will grow by 5.1% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure. Highlighted with 62 tables and 55 figures, this 142-page report 鈥淓urope Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Europe preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023...Read more	USD 2,600.00
Asia Pacific Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity Asia Pacific preventive vaccines market will grow by 7.9% annually with a total addressable market cap of $217.46 billion over 2023-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure. Highlighted with 59 tables and 54 figures, this 141-page report 鈥淎sia Pacific Preventive Vaccines 麻豆原创 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022...Read more	USD 2,600.00
Global Nicotinamide Riboside (NR) 麻豆原创 Report, History and Forecast 2018-2029 Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Nicotinamide Riboside (NR) was estimated at US$ 21.46 million in the year 2022, is projected to reach a revised size of US$ 38.76 million by 2029, growing at a CAGR of 8.32 % during the forecast period 2023-2029. North American market for Nicotinamide Riboside (NR) was valued at $ 9.78 million in 2022 and will reach $ 17.90 million by 2029, at a CAGR of 8.49 % during the forecast period of 2023 through 2029. Asia-Pacific market for Nicotinamide Riboside (NR) was valued at $ 6.55 million in 2022 and will reach $ 12.26 million by 2029, at a CAGR of 9.08 % during the forecast period of 2023 through 2029. Europe market for Nicotinamide Riboside (NR) was valued at $ 3.59 million in 2022 and will reach $ 6.26 million by 2029, at a CAGR of 7.35 % during the forecast period of ...Read more	USD 4,900.00

Clients Who Trust Us

Need tailor made market research solution? We can help you with that too.

Contact Us

About Us

At 麻豆原创 we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer鈥檚 needs, be it custom research or syndicated research reports.

Contact Us

麻豆原创 Research Reports, Inc
16192 Coastal Hwy
Lewes, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

Latest Blog Posts

Stay Connected

Disclaimer: 麻豆原创 has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom market research from our website 麻豆原创ResearchReports.com only.

If you are looking for a market research solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us.

麻豆原创